Zepbound (Tirzepatide) Dosing in Menopause: Schedule & Care

7 minute read

By: Alloy Health Editorial Team|Last updated: November 18, 2026|Medically reviewed by: Dr. Kathryn Williams
Plus size woman preparing a light breakfast of fruits. header

Summary

Tirzepatide, also known by its brand name ZepboundⓇ, is a once-weekly medication used for chronic weight management, but finding the right dose isn’t a race to 15 mg. The goal is to find a dose that works for you while keeping side effects manageable. 

Why weight gain can feel different during perimenopause and menopause

During midlife, you may notice differences in your weight and body composition even when your usual eating and exercise habits haven’t changed. Both normal aging and the transition to menopause can contribute to this, but they do it in different ways.

As estrogen levels decline, fat distribution tends to shift toward the abdomen. At the same time, age-related changes in muscle mass and energy expenditure can influence how your body stores fat. Menopause symptoms, including disrupted sleep and hot flashes, can also make it harder to maintain your usual health routines.

These changes don't necessarily mean that weight gain is inevitable or that it requires treatment. But if you are looking to lose weight as part of a healthy lifestyle or to reduce risk factors and are considering medical weight management, understanding the changes occurring during midlife can help you have more informed conversations with your clinician.

What is Tirzepatide?

Tirzepatide is a prescription, once-weekly medication that mimics two natural gut hormones. These hormones act on pathways in the body to reduce hunger signals and slow gastric emptying, which can help you feel full sooner and for longer. Tirzepatide is different from some other GLP-1 medications because it works on two hormone pathways that can help with weight loss, glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). 

Tirzepatide is approved for adults with obesity or to treat adults with excess weight who have at least one weight-related medical condition. It is intended to be used along with a reduced calorie diet and increased physical activity.

Like other GLP-1 medications, tirzepatide can cause some gastrointestinal side effects, especially at first and after dose increases. Starting low and increasing slowly helps keep them manageable.

Zepbound

Zepbound®

Starting at $299 /month

Tirzepatide (Zepbound) Dosing: Start Low and Increase Slow

Starting Doses - Weeks 1-4: Treatment with tirzepatide usually starts at 2.5 mg once weekly for four weeks. This is a small dose and may not cause much weight loss, but it's intended to help your body adjust to the medicine. Once you and your doctor know that you are tolerating the medication well, the dose can then be increased.

First Increases - Weeks 5-8: 5 mg once weekly. 

You can move up a dose as often as every four weeks, following the rest of this schedule, but how fast you go depends on how well you’re tolerating the medication and how much weight loss is right for you.

Weeks 9-12 (month 3): 7.5 mg once weekly

Weeks 13-16 (month 4): 10 mg once weekly

Weeks 17-20 (month 5): 12.5 mg once weekly

Weeks 21+ (month 6+): 15 mg once weekly

This may show a possible path to the top, but not everyone needs the highest dose. Many people achieve their treatment goals with a lower maintenance dose than 15 mg, such as 5 or 10 mg. It depends on many individual factors and open communication with your doctor. Likewise, you don’t have to increase the dose every 4 weeks. This schedule is the soonest someone could titrate to the highest dose, not when everyone should. 

Zepbound Kwikpen

Zepbound® KwikPen®

Starting at $299 /month

What You Might Notice During the First Few Months

Some people notice changes in their appetite or how quickly they feel full soon after starting tirzepatide. Changes in weight may take longer to become noticeable, especially during the first month when you're taking the introductory dose. As treatment continues, you may notice differences in your appetite, portion sizes, and eating habits. Your response will depend on several factors, including your dose, how well you tolerate the medication, and your individual health needs.

Not everyone responds to tirzepatide at the same pace. Your clinician will monitor your progress and help determine whether adjustments are appropriate as treatment continues.

Staying Healthy on Zepbound

Weight loss is only one measure of treatment success on tirzepatide. Tirzepatide can reduce your appetite, but you still need enough food and fluids to stay healthy. Stronger appetite suppression is not automatically better, especially if it becomes difficult to meet basic nutritional needs. Weight loss can also involve the loss of muscle, not just body fat. This is especially relevant during midlife, when aging and the menopause transition may already affect muscle mass and body composition. 

Healthy treatment should account for nutrition, hydration, strength, physical function, and body composition, along with changes on the scale. Getting enough protein and incorporating resistance exercises, such as lifting weights, can help maintain muscle mass during treatment with a GLP-1. 

Compounded Terizepatide

Compounded Tirzepatide

Starting at $100 /month

What to Be Aware of While Taking Zepbound

Common side effects of tirzepatide include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, burping, and reflux. These effects often occur when first starting the medication or during dose increases and typically improve with continued use.

Staying healthy on this medication means being able to eat enough, stay hydrated, carry out normal activities, and avoid side effects that are burdensome. If a higher dose makes eating, drinking, or functioning normally difficult, talk with the prescribing doctor.

Vomiting and diarrhea can make it hard to stay hydrated. Get prompt medical care for signs of severe dehydration, severe abdominal pain, or other concerning symptoms.

Can Hormone Replacement Therapy Be Taken with Zepbound?

If you take hormone replacement therapy (HRT) and are curious about tirzepatide, you might wonder whether the two treatments affect each other. HRT and tirzepatide can be prescribed together when appropriate, although research on their combined use is still limited.

Tirzepatide slows stomach emptying, which can reduce the effectiveness of oral hormonal contraceptives. If you take birth control pills, the FDA recommends using a nonoral contraceptive method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase.

 

Questions to Ask Before Increasing Your Dose

  • Is my current dose working?

  • Why are we considering an increase now?

  • How much additional benefit will I get with this increased dose? Is it just weight loss or something else?

  • Am I tolerating my current dose well, or are side effects getting in the way?

  • Can I eat enough, stay hydrated, and maintain my usual activities?

  • Which side effects should prompt me to contact you?

  • How will we choose the right maintenance dose for me?

  • How does tirzepatide fit with my other medications and menopause care?

 

Finding the Dose That’s Right For You

Tirzepatide can be an effective treatment for women who are appropriate candidates, but treatment isn't a race through every available dose. The right maintenance dose may look different for each woman. What matters is finding a dose that supports your individual health goals while allowing you to feel well and enjoy your everyday life.


Frequently Asked Questions

How does the tirzepatide (Zepbound) dosing schedule work, and do you have to reach the maximum dose?

Treatment with tirzepatide typically starts at 2.5 mg once weekly for the first four weeks to allow your body to adjust to the medication. Depending on how well you tolerate it, your doctor may increase the dose as often as every four weeks—moving to 5 mg in weeks 5–8, 7.5 mg in weeks 9–12, 10 mg in weeks 13–16, 12.5 mg in weeks 17–20, and up to 15 mg once weekly from week 21 onward. However, treatment is not a race to the highest dose, and you do not have to increase every four weeks. Many people achieve their weight-management goals on a lower maintenance dose, such as 5 mg or 10 mg, while keeping side effects manageable.

Can you take tirzepatide alongside hormone replacement therapy (HRT) or birth control pills?

Hormone replacement therapy (HRT) and tirzepatide can be prescribed together when clinically appropriate, although research on their combined use is still limited. However, because tirzepatide slows down how quickly your stomach empties, it can make oral hormonal contraceptives less effective. If you take birth control pills, the FDA recommends using a nonoral contraceptive method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after every dose increase.

How can you manage side effects and protect muscle mass while taking tirzepatide during menopause?

Common gastrointestinal side effects—including nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, burping, and reflux—most often occur when starting the medication or increasing doses and usually improve with continued use, though severe dehydration or severe abdominal pain requires prompt medical attention. Because weight loss typically reduces both body fat and muscle tissue during a life stage when menopause and aging already affect body composition, it is important to stay hydrated, consume adequate dietary protein, and incorporate resistance exercises such as lifting weights to preserve strength and lean muscle mass.

 


References

  1. Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use [prescribing information]. Revised August 2026. Accessed September 14, 2026.

  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.

  3. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. doi:10.1172/jci.insight.124865.

  4. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.

  5. Palmer K. Telehealth firms pivot from GLP-1 weight loss drugs to hormone replacement therapy. STAT. Published March 11, 2025. Accessed September 14, 2026.

Related Content

  1. https://www.myalloy.com/solutions/zepbound

  2. https://www.myalloy.com/blog/how-long-until-tirzepatide-works

  3. https://www.myalloy.com/blog/how-to-lose-weight-during-menopause

  4. https://www.myalloy.com/solutions

  5. https://www.myalloy.com/perimenopause

  6. https://myalloy.zendesk.com/hc/en-us/articles/39471023349523-Can-I-take-GLP-1-medication-with-Menopausal-Hormone-Therapy-MHT

  7. https://www.myalloy.com/blog/menopause-weight-gain-diet-exercise

  8. https://www.youtube.com/watch?v=wqOCXS-SWO8

  9. https://www.youtube.com/watch?v=80kqLuRkTmk

Citations

  1. Santiago Palacios, Peter Chedraui, Rafael Sanchez-Borrego, Pluvio Coronado, Tommaso Simoncini, Katrin Schauding, et al.. Management of obesity in menopause. Climacteric 2024;27(4):357-363. PMID:39016333.

    View source
  2. Hana Mikdachi, Rebecca Dunsmoor-Su. GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence. Curr Opin Obstet Gynecol 2025;37(2):97-101. PMID:39970049.

    View source
  3. Joana Nicolau, Jorge Blanco-Anesto, Aina Bonet, Juan José Félix-Jaume, Apolonia Gil-Palmer. Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause. Metab Syndr Relat Disord 2025;23(1):70-76. PMID:39761057.

    View source
  4. Maneeha Naveed, Cecilie Perez, Ehtasham Ahmad, Laura Russell, Zoe Lees, Catriona Maybury. GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting. Diabetes Obes Metab 2025;27(7):3780-3788. PMID:40259493.

    View source
  5. Christoph Kapitza, Leszek Nosek, Lene Jensen, Helle Hartvig, Christine B Jensen, Anne Flint. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol 2015;55(5):497-504. PMID:25475122.

    View source
  6. Jose A Santos-Marcos, Oriol A Rangel-Zuñiga, Rosa Jimenez-Lucena, Gracia M Quintana-Navarro, Sonia Garcia-Carpintero, Maria M Malagon, et al.. Influence of gender and menopausal status on gut microbiota. Maturitas 2018;116:43-53. PMID:30244778.

    View source
  7. Reis-Barbosa PH, Marcondes-de-Castro I, Marinho TS, et al. The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice. Diabetes Obes Metab. 2024;26(10):4613-4621. PMID:39113264.

    View source

Share this post

Subscribe

Go ahead, you deserve to

feel fantastic

Stay connected

Follow us